protein

MAP

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about MAP: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

91Connections

18Hypotheses

3Analyses

50Outgoing

36Incoming

12Experiments

5Debates

Summary

DUSP6 (also known as MKP3) is a dual-specificity phosphatase that specifically dephosphorylates and inactivates ERK1/2. It functions as a negative regulator of MAPK signaling and has been implicated in neurodegenerative diseases including Parkinson's disease.

View on Wiki →

AI-generated illustration · click image to enlarge

Regenerate portrait ↻

🔬 Protein Info

Gene Symbol	MAP
Aliases	also known as MKP3
Molecular Weight	39.8 kDa
Pathways	pathway: [@dusp6_erk2019], MAPK pathway, MAPK, MAPK Signaling
GeneCards	MAP
Human Protein Atlas	MAP
Associated Diseases	ALS, Alzheimer, Alzheimer's disease, neurodegeneration, neuroinflammation, Parkinson
Interactions	ALZHEIMER, BDNF, CD33, CD44, CDK5, CX3CL1
KG Connections	91 knowledge graph edges
Databases	GeneCards UniProt NCBI Gene HPA STRING

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    MAP["MAP"]
    CD33(["CD33"])
    MAP -->|"activates"| CD33
    P2RY1(["P2RY1"])
    MAP -->|"co_discussed"| P2RY1
    P2RY12(["P2RY12"])
    MAP -->|"activates"| P2RY12
    CD44(["CD44"])
    MAP -->|"activates"| CD44
    NEURON(["NEURON"])
    MAP -->|"co_discussed"| NEURON
    WAS(["WAS"])
    MAP -->|"co_discussed"| WAS
    ALZHEIMER(["ALZHEIMER"])
    ALZHEIMER -->|"interacts_with"| MAP
    GENES(["GENES"])
    GENES -->|"co_discussed"| MAP
    HCRTR1(["HCRTR1"])
    HCRTR1 -->|"co_discussed"| MAP
    HCRTR2(["HCRTR2"])
    HCRTR2 -->|"interacts_with"| MAP
    style MAP fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#4fc3f7

Outgoing (55)

Target	Relation	Type	Str
neuroinflammation	activates	disease	0.80
MAPK signaling	participates_in	pathway	0.80
Wnt signaling	participates_in	pathway	0.60
autophagy pathway	participates_in	pathway	0.60
MLKL	activates	gene	0.60
neurodegeneration	activates	disease	0.60
oligodendrocytes	expressed_in	cell_type	0.60
TGF-beta signaling	participates_in	pathway	0.60
ALS	associated_with	disease	0.60
PS1	associated_with	gene	0.60
epigenetic regulation	participates_in	pathway	0.60
Alzheimer's disease	inhibits	disease	0.60
NF-kB signaling	participates_in	pathway	0.60
ubiquitin-proteasome	participates_in	pathway	0.60
VGLUT1	inhibits	gene	0.60
TNF	activates	gene	0.60
neuroinflammation	causes	disease	0.60
MRPS31	expressed_in	gene	0.60
RIPK2	expressed_in	gene	0.60
UHRF1	expressed_in	gene	0.60
necroptosis	participates_in	pathway	0.60
PGAM5	associated_with	gene	0.60
PINK1	associated_with	gene	0.60
PTEN	regulates	gene	0.60
apoptosis pathway	participates_in	pathway	0.60
oxidative stress response	participates_in	pathway	0.60
MAPK	expressed_in	gene	0.60
MAPK7	expressed_in	gene	0.60
ROS	regulates	gene	0.60
P38	activates	gene	0.60
TNF	targets	gene	0.60
synaptic plasticity	participates_in	pathway	0.60
neurodegeneration	associated_with	disease	0.60
Parkinson	associated_with	disease	0.60
Alzheimer	associated_with	disease	0.60
Alzheimer's disease	causes	disease	0.60
microglia	expressed_in	cell_type	0.55
astrocytes	expressed_in	cell_type	0.55
insulin signaling	participates_in	pathway	0.55
neurons	expressed_in	cell_type	0.55
MAP6	associated_with	gene	0.55
MAP2	regulates	gene	0.55
CD33	activates	gene	0.50
GAD1	inhibits	gene	0.50
WAS	regulates	protein	0.50
STING	co_discussed	gene	0.50
DYSTROPHIN	inhibits	protein	0.50
WAS	co_discussed	protein	0.50
NEURON	co_discussed	gene	0.50
CD44	activates	gene	0.50

Incoming (36)

Source	Relation	Type	Str
GSK3	activates	gene	0.60
HCRTR1	interacts_with	gene	0.60
JNK1	activates	gene	0.60
JNK2	activates	gene	0.60
DNA	regulates	gene	0.60
CX3CL1	activates	gene	0.60
CX3CR1	activates	gene	0.60
LOX	associated_with	gene	0.60
MAO	associated_with	gene	0.60
CDK5	activates	gene	0.60
ERK1	activates	gene	0.60
AKT	associated_with	gene	0.60
ERK	associated_with	gene	0.60
APP	associated_with	gene	0.60
GFAP	associated_with	gene	0.60
BDNF	inhibits	gene	0.60
ATM	regulates	gene	0.60
ABCA7	expressed_in	gene	0.60
ARF1	expressed_in	gene	0.60
ATG7	expressed_in	gene	0.60
E2F2	expressed_in	gene	0.60
ELAVL1	expressed_in	gene	0.60
G6PD	expressed_in	gene	0.60
GRID2	expressed_in	gene	0.60
HCRTR1	biomarker_for	gene	0.60
HCRTR2	biomarker_for	gene	0.60
ALZHEIMER	interacts_with	gene	0.50
GENES	co_discussed	gene	0.50
HCRTR1	co_discussed	gene	0.50
JNK1	co_expressed_with	gene	0.50
JNK2	co_expressed_with	gene	0.50
BCL2	co_expressed_with	gene	0.50
BNIP3	co_expressed_with	gene	0.50
CBL	co_expressed_with	gene	0.50
ERK	co_expressed_with	protein	0.50
HCRTR2	interacts_with	gene	0.50

Targeting Hypotheses (18)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Tau/MAP6 ratio as a master switch for microtubule dynamics p	0.750	neurodegeneration	View
MAP6-CRMPS cooperative phosphorylation by GSK3β	0.700	neurodegeneration	View
Excitatory Neuron Synaptic Dysfunction and Mitochondrial Str	0.660	neurodegeneration	Cell type vulnerability debate in Alzhei
Tau/MAP6 antagonism in neurodegeneration progression	0.650	neurodegeneration	View
DLK MAPK Pathway Inhibition to Block Tau-Induced Neurotoxici	0.634	neurodegeneration	Should microtubule-stabilizing drugs be

Rutin stabilizes a non-nucleating tau conformer through dire	0.627	neurodegeneration	What is the molecular mechanism by which
ATF4-DDIT3 stress signaling indirectly represses MAPT transc	0.624	neurodegeneration	Which specific transcription factors med
Activity-dependent MAP6 scaffolding at synapses	0.600	neurodegeneration	View
HSF1 reprioritizes transcription and suppresses MAPT while r	0.598	neurodegeneration	Which specific transcription factors med
Tau-Independent Microtubule Stabilization via MAP6 Enhanceme	0.567	neurodegeneration	Selective vulnerability of entorhinal co
Developmental stage-specific dominance of tau vs MAP6 functi	0.550	neurodegeneration	View
REST-like neuronal silencing programs suppress MAPT in sever	0.506	neurodegeneration	Which specific transcription factors med
MAP6-mediated microtubule stabilization as therapeutic targe	0.500	neurodegeneration	View
CX3CR1 PET with Nano-bodies for Microglial Surveillance Stat	0.477	biomarkers	What biomarkers can reliably detect micr
Astrocyte CD38-erk Mapk signaling controls mitochondrial tra	0.380	ALS and Alzheimer's disease	Mitochondrial transfer between neurons a
AD fine-mapping identifies causal variants in microglia-spec	0.380	Alzheimer's disease	Statistical Fine-Mapping of AD GWAS Loci
CREB-Mediated Differential CD55/CD46 Expression Creates Acti	0.380	synaptic biology	What determines the selectivity of compl
CREB-Mediated Differential CD55/CD46 Expression Creates Acti	0.380	synaptic biology	What determines the selectivity of compl

Mentioning Analyses (3)

Scientific analyses that reference this entity

Which specific transcription factors mediate MAPT suppression during proteostati

neurodegeneration | 2026-04-25 | 3 hypotheses Top: 0.624

Proteomics Differential Expression in AD CSF and Brain Tissue

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.865

Cas13 gRNA Design for Silencing MAPT (Tau) Transcripts in Alzheimer's Disease

neurodegeneration | 2026-04-16 | 0 hypotheses

Experiments (12)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
iPSC-derived astrocyte-neuron co-culture mitochondrial transfer in PD	exploratory	Parkinson's disease	0.900	0.00	iPSC-derived dopaminergic neur	proposed	N/A
Autophagy receptor identification for stress granule elimination	exploratory	neurodegenerative diseases	0.900	0.00	cultured cells under arsenite	proposed	N/A
MAP6 depletion effects on neuronal development in primary cultures	exploratory		0.900	0.00	primary rodent neuronal cultur	proposed	N/A
MAP6 depletion effects on neuronal development in primary cultures	exploratory		0.900	0.00	primary rodent neuronal cultur	proposed	N/A
In vivo neuronal migration assay with MAP6 depletion	validation		0.850	0.00	rodent in vivo model	proposed	N/A
4R-Tau Targeting Therapies for PSP and CBS	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$6,550,000
Anti-Tau Immunotherapy Dosing Optimization	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy in 4R-Tau	validation	Neurodegeneration	0.400	0.50	cell_line	proposed	$170,000
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Trials Have N	clinical	ALS	0.400	0.50	human	proposed	$7,500,000
Axonal Transport Dysfunction Validation in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$6,550,000
Blood Biomarker vs Tau PET for Treatment Monitoring	clinical	ALS	0.400	0.50	human	proposed	$5,460,000
CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omics Study	validation	Neurodegeneration	0.400	0.50	cell_line	proposed	$160,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Tau and MAP6 establish labile and stable domains on microtubules. [PMID:40040809]	Kirimtay K, Huang W, Sun X, Qiang L, Wan	iScience	2025	1
Antagonistic roles of tau and MAP6 in regulating neuronal development. [PMID:39257379]	Sun X, Yu W, Baas PW, Toyooka K, Qiang L	J Cell Sci	2024	1
Beyond Neuronal Microtubule Stabilization: MAP6 and CRMPS, Two Converging Storie [PMID:34025352]	Cuveillier C, Boulan B, Ravanello C, Den	Front Mol Neurosci	2021	1
Tau: It's Not What You Think. [PMID:30929793]	Baas PW, Qiang L	Trends Cell Biol	2019	1
Stability properties of neuronal microtubules. [PMID:26887570]	Baas PW, Rao AN, Matamoros AJ, Leo L	Cytoskeleton (Hoboken)	2016	1
Targeting CXCL16-expressing macrophages with a biomimetic nanocarrier system att [PMID:41707770]	Yang Q, Xu Y, Zhan Y, Li J, Peng R, Yu B	Journal of controlled release	2026	0
The MAP6-NTS axis in hippocampal CA1 regulates synaptic plasticity and memory. [PMID:41825505]	Jia Y, Lei J, Jiang Y, Xue L, Chen T, Wa	Neuropharmacology	2026	0
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025	0
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025	0
BioID2-Based Tau Interactome Reveals Novel and Known Protein Interactions Associ [PMID:40910579]	Atwa A, Alhadidy MM, Lamp J, Combs B, Ka	Journal of proteome research	2025	0
Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acid [PMID:40533746]	["Sanadgol N", "Abedi M", "Hashemzaei M"	Journal of nanobiotechnology	2025	0
P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting [PMID:38513667]	Zhang D, Zhang W, Ming C, Gao X, Yuan H,	Neuron	2024	0
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554]	Marogianni C, Sokratous M, Dardiotis E,	International journal of molec	2020	0
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554]	Marogianni C, Sokratous M, Dardiotis E,	International journal of molec	2020	0
Tau protein aggregation is associated with cellular senescence in the brain. [PMID:30126037]	["Musi Nicolas", "Valentine Joseph M", "	Aging cell	2018	0
Multiple Sclerosis Pathology. [PMID:29358320]	Lassmann H	Cold Spring Harbor perspective	2018	0
ReMAPping the microtubule landscape: How phosphorylation dictates the activities [PMID:28980356]	Ramkumar A, Jong BY, Ori-McKenney KM	Developmental dynamics : an of	2018	0
Tau protein aggregation is associated with cellular senescence in the brain. [PMID:30126037]	["Musi Nicolas", "Valentine Joseph M", "	Aging cell	2018	0
Inferring patterns of folktale diffusion using genomic data. [PMID:28784786]	["Bortolini E", "Pagani L", "Crema E", "	Proceedings of the National Ac	2017	0
Purification and Characterization of Progenitor and Mature Human Astrocytes Reve [PMID:26687838]	["Zhang Y", "Sloan S", "Clarke L", "Cane	Neuron	2016	0

Debates (5)

Multi-agent debates referencing this entity

Which specific transcription factors mediate MAPT suppression during proteostati

closed · Rounds: 4 · Score: 0.66 · 2026-04-25

Can optimized Cas13 guide RNAs selectively silence pathogenic MAPT splice varian

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

Which proteins are differentially expressed in AD CSF and brain tissue, and do t

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

Is a 12-protein CSF panel superior to existing plasma p-tau217 for clinical AD p

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

Is Cas13-based 4R-tau silencing feasible given collateral cleavage risks in post

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

Related Research

Hypotheses and analyses mentioning MAP in their description or question text

MAP

Understanding Entity Pages

Summary

Wiki Pages (21)

Cerebral Autoregulation in Neurodegeneration

BIIB080 (MAPTRx) Antisense Oligonucleotide for Alzheimer's Disease

MAPK9 Gene

MAPK/ERK Signaling Pathway in Neurodegeneration

MAP1LC3A Gene

MAPT→Tau→Aggregation→PSP Causal Chain

Pathway Diagram

Outgoing (55)

Incoming (36)

Targeting Hypotheses (18)

Mentioning Analyses (3)

Which specific transcription factors mediate MAPT suppression during proteostati

Proteomics Differential Expression in AD CSF and Brain Tissue

Cas13 gRNA Design for Silencing MAPT (Tau) Transcripts in Alzheimer's Disease

Experiments (12)

Related Papers (20)

Debates (5)

Which specific transcription factors mediate MAPT suppression during proteostati

Can optimized Cas13 guide RNAs selectively silence pathogenic MAPT splice varian

Which proteins are differentially expressed in AD CSF and brain tissue, and do t

Is a 12-protein CSF panel superior to existing plasma p-tau217 for clinical AD p

Is Cas13-based 4R-tau silencing feasible given collateral cleavage risks in post

Related Research

Rutin stabilizes a non-nucleating tau conformer through direct MAPT repeat-domai

ATF4-DDIT3 stress signaling indirectly represses MAPT transcription during prote

Activity-dependent MAP6 scaffolding at synapses

HSF1 reprioritizes transcription and suppresses MAPT while restoring proteostasi

Tau-Independent Microtubule Stabilization via MAP6 Enhancement

Developmental stage-specific dominance of tau vs MAP6 function

REST-like neuronal silencing programs suppress MAPT in severe proteostatic stres

MAP6-mediated microtubule stabilization as therapeutic target

CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping

Astrocyte CD38-erk Mapk signaling controls mitochondrial transfer to neurons via

AD fine-mapping identifies causal variants in microglia-specific enhancers with

CREB-Mediated Differential CD55/CD46 Expression Creates Activity-Dependent Compl

CREB-Mediated Differential CD55/CD46 Expression Creates Activity-Dependent Compl

MAP

Understanding Entity Pages

Summary

Wiki Pages (21)

Cerebral Autoregulation in Neurodegeneration

BIIB080 (MAPTRx) Antisense Oligonucleotide for Alzheimer's Disease

MAPK9 Gene

MAPK/ERK Signaling Pathway in Neurodegeneration

MAP1LC3A Gene

MAPT→Tau→Aggregation→PSP Causal Chain

MAP2K5

MAP6 Gene

JNK/p38 MAPK Signaling Pathway in Neurodegeneration

MAP3K6 Gene

BIIB080 (MAPTRx)

MAP3K4 — Mitogen-Activated Protein Kinase Kinase Kinase 4

MAP2K2 Gene

MAP2K3 Protein (MEK3)

Tau-MAPT-Tubulin Assembly

BIIB080 (MAPTRx) ASO Therapy for PSP

JNK/p38 MAPK Inhibitor Companies for Parkinson's Disease

MAP2K7

MAPT - Microtubule-Associated Protein Tau

MAP3K3 Gene

MAP3K5 — Mitogen-Activated Protein Kinase Kinase Kinase 5

Pathway Diagram

Outgoing (55)

Incoming (36)

Targeting Hypotheses (18)

Mentioning Analyses (3)

Which specific transcription factors mediate MAPT suppression during proteostati

Proteomics Differential Expression in AD CSF and Brain Tissue

Cas13 gRNA Design for Silencing MAPT (Tau) Transcripts in Alzheimer's Disease

Experiments (12)

Related Papers (20)

Debates (5)

Which specific transcription factors mediate MAPT suppression during proteostati

Can optimized Cas13 guide RNAs selectively silence pathogenic MAPT splice varian

Which proteins are differentially expressed in AD CSF and brain tissue, and do t

Is a 12-protein CSF panel superior to existing plasma p-tau217 for clinical AD p

Is Cas13-based 4R-tau silencing feasible given collateral cleavage risks in post

Related Research

Rutin stabilizes a non-nucleating tau conformer through direct MAPT repeat-domai

ATF4-DDIT3 stress signaling indirectly represses MAPT transcription during prote

Activity-dependent MAP6 scaffolding at synapses

HSF1 reprioritizes transcription and suppresses MAPT while restoring proteostasi

Tau-Independent Microtubule Stabilization via MAP6 Enhancement

Developmental stage-specific dominance of tau vs MAP6 function

REST-like neuronal silencing programs suppress MAPT in severe proteostatic stres

MAP6-mediated microtubule stabilization as therapeutic target

CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping

Astrocyte CD38-erk Mapk signaling controls mitochondrial transfer to neurons via

AD fine-mapping identifies causal variants in microglia-specific enhancers with

CREB-Mediated Differential CD55/CD46 Expression Creates Activity-Dependent Compl

CREB-Mediated Differential CD55/CD46 Expression Creates Activity-Dependent Compl